NASDAQ · Medical Care Facilities · USD
COMPASS Pathways plc (CMPS) Stock Analysis
COMPASS Pathways plc (CMPS) is a Medical Care Facilities stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CMPS Key Statistics
As of Sep 4, 2026Trading
- Open
- $13.17
- Previous Close
- $13.29
- Day's Range
- 13.05–13.38
- 52-Week Range
- 4.82–15.40
- Volume
- 789.00K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.55
Valuation
- Market Cap
- $1.84B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.79
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$287.86M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 138.48M
- 1-Year Return
- +160.20%
Dividend and dates
- Earnings Date
- November 3, 2026
- Avg Volume
- 3.40M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
CMPS Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +92.32% |
| 2025 | +82.54% |
| 2024 | −56.80% |
| 2023 | +8.97% |
| 2022 | −63.67% |
| 2021 | −53.61% |
| 2020 (partial year) | +64.28% |
As of September 4, 2026.
CMPS Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$287.86M | — |
| 2024 | $0.00 | −$155.12M | — |
| 2023 | $0.00 | −$118.46M | — |
| 2022 | $0.00 | −$91.51M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$175.29M | −$287.86M | — |
| 2024 | $0.00 | — | −$157.11M | −$155.12M | — |
| 2023 | $0.00 | — | −$124.04M | −$118.46M | — |
| 2022 | $0.00 | — | −$95.98M | −$91.51M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
CMPS Valuation vs Medical Care Facilities Median
Median of 57 stocks| Metric | CMPS | Medical Care Facilities median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 3.06% | 3.1 pts below |
Medians across 57 Medical Care Facilities stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YahooCompass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
YahooCompass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
YahooCompass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization
SeekingAlphaCompass Pathways: Still A Buy, But The Exit Just Got Complicated
SeekingAlphaCMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
Yahoo
All 20 articles ↓Show fewer ↑
COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript
YahooCompass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
YahooHC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65
BenzingaMorgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
BenzingaRBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21
BenzingaB. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22
BenzingaCompass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Controlled Clinical Trial
BenzingaCompass Pathways Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
BenzingaCOMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript
SeekingAlphaCompass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss
ChartMillUPDATE: Compass Pathways Q2 Adj. EPS $(0.36) Beats $(0.40) Estimate. (Adj EPS excludes Fair value change of warrant liabilities)
BenzingaCompass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate
BenzingaCompass Pathways: The Psilocybin Biotech Leader With Strong Momentum
SeekingAlphaWells Fargo Initiates Coverage On Compass Pathways with Equal-Weight Rating, Announces Price Target of $13
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Medical Care Facilities Stocks
HCA Healthcare, Inc.
$87.68B
THCTenet Healthcare Corporation
$21.34B
FMSFresenius Medical Care AG
$12.06B
EHCEncompass Health Corporation
$12.01B
DVADaVita Inc.
$11.74B
UHSUniversal Health Services, Inc.
$10.00B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B














